SCHEMBL6779729

SCHEMBL6779729

CC(C)(C)C=O.Cn1c(CNc2ccc(C#N)cc2)nc2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 14/20 0.60
RAB9A P51151 14/20 0.60
SMN1; SMN2 Q16637 8/20 0.60
KDM4E B2RXH2 4/20 0.60
TP53 P04637 4/20 0.60
ALDH1A1 P00352 4/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
NFKB1 P19838 2/20 0.60
NFKB2 Q00653 2/20 0.60
RELA Q04206 2/20 0.60
ALOX15 P16050 1/20 0.60
MAPT P10636 5/20 0.59
LMNA P02545 5/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
GFER P55789 2/20 0.59
MAPK1 P28482 1/20 0.59
GAA P10253 4/20 0.54
KLK1 P06870 1/20 0.54
KLK5 Q9Y337 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7447463 0.91 NPC1 (0.72) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL7163084 0.81 HDAC6 (0.44) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL19339630 0.79 HDAC6 (0.48) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL14914339 0.77 HDAC6 (0.51) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL31243047 0.77 NPC1 (1.00) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL7415015 0.76 NPC1 (0.61) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL16268668 0.76 NPC1 (0.50) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL6779723 0.75 HDAC6 (0.49) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL2245500 0.75 NPC1 (1.00) NPC1RAB9ASMN1; SMN2KDM4ETP53
SCHEMBL13779307 0.75 NPC1 (1.00) NPC1RAB9ASMN1; SMN2KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710055-B2 INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBO QUINOLINE-8-SULFONYLAMINO)-INDOLE BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2004-03-23 US disclosed
US-20030004181-A1 Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-01-02 US disclosed
US-6414008-B1 CYNAO- OR AMIDINE-SUBSTITUTED BENZIMIDAZOLES, BENOTHIAZOLES, OR BENZOXAZOLES; 2-(N-(4-AMIDINOPHENYL)AMINOMETHYL)BENZOTHIAZOLES; 2-((4-CYANOPHENYL)OXYMETHYL)IMIDAZOL(4,5-B)PYRIDINES; ANTITHROMBOTICS BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004181-A1 Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions F2, TFPI, FGB NPC1 2986/4885RAB9A 531/4885SMN1; SMN2 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.